Gyre Therapeutics (GYRE) Shares Outstanding (Diluted Average) (2010 - 2023)

Gyre Therapeutics (GYRE) has 6 years of Shares Outstanding (Diluted Average) data on file, last reported at $37.8 million in Q3 2023.

• Shares Outstanding (Diluted Average) for Q3 2023 came in at $37.8 million, up 19.74% year-over-year; the trailing twelve-month figure through Sep 2023 was $37.8 million (up 19.74% YoY), and the FY2022 annual result was $31.5 million, up 2.95% from the prior year.
• Shares Outstanding (Diluted Average) was little changed at $37.8 million in Q3 2023 per GYRE's latest filing, from $37.8 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $38.0 million in Q1 2023 and troughed at $30.4 million in Q3 2021.
• A 3-year average of $33.2 million and a median of $31.5 million in 2022 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Diluted Average) climbed 0.43% in 2022, then increased 20.75% in 2023.
• A 3-year view of Shares Outstanding (Diluted Average) shows it stood at $30.6 million in 2021, then increased by 2.95% to $31.5 million in 2022, then gained by 19.97% to $37.8 million in 2023.
• Business Quant data shows GYRE's Shares Outstanding (Diluted Average) at $37.8 million in Q3 2023, $37.8 million in Q2 2023, and $38.0 million in Q1 2023.